Delayed Chemotherapy-induced Nausea and Vomiting in Autologous Hematopoietic Cell Transplant Patients: An Exploratory Analysis

Ettinger DS Bierman PJ Bradbury B et al; National comprehensive Cancer Network (NCCN). Antiemesis. J Natl Compr Canc Netw 2007;5 (1):12–33

López-Jiménez J Martín-Ballesteros E Sureda A Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006;91 (1):84–91

Gonella S Berchialla P Bruno B Di Giulio P Are orange lollies effective in preventing nausea and vomiting related to dimethyl sulfoxide? A multicenter randomized trial. Support Care Cancer 2014;22 (9):2417–2424

Schwartzberg LS Jacobs P Matsouka P Azevedo W Pinto A The role of second-generation 5-HT3 receptor antagonists in ­managing chemotherapy-induced nausea and vomiting in hematological malignancies. Crit Rev Oncol Hematol 2012;83 (1):59–70

Saito M Aogi K Sekine I Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10 (2):115–124

Hesketh PJ Grunberg SM Gralla RJ et al; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin: the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21 (22):4112–4119

Poli-Bigelli S Rodrigues-Pereira J Carides AD et al; Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97 (12):3090–3098

Aapro M Molassiotis A Dicato M et al; PEER investigators. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012;23 (8):1986–1992

Burmeister H Aebi S Studer C Fey MF Gautschi O Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 2012;20 (1):141–147

Roila F Herrstedt J Aapro M et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21Suppl (5):v232–v243

Gomez DR Liao KP Giordano S Nguyen H Smith BD Elting LS Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer 2013;119 (7):1428–1436

Koch S Wein A Siebler J Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project. Support Care Cancer 2013;21 (9):2395–2402

Gilmore JW Peacock NW Gu A Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 2014;10 (1):68–74

Stiff PJ Fox-Geiman MP Kiley K Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2013;19 (1):49–55 e1

Santos NC Figueira-Coelho J Martins-Silva J Saldanha C Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003; 65 (7):1035–1041

Prior D Mitchell A Nebauer M Smith M Oncology nurses’ experience of dimethyl sulfoxide odor. Cancer Nurs 2000;23 (2): 134–140

Potter P Eisenberg S Cain KC Berry DL Orange interventions for symptoms associated with dimethyl sulfoxide during stem cell reinfusions: a feasibility study. Cancer Nurs 2011;34 (5): 361–368

Cox MA Kastrup J Hrubiško M Historical perspectives and the future of adverse reactions associated with haemopoietic stem cells cryopreserved with dimethyl sulfoxide. Cell Tissue Bank 2012;13 (2):203–215

Fabi A Malaguti P An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother 2013;14 (5):629–641

Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012 ISBN 3-900051-07-0.

Patriarca F Petrucci MT Bringhen S Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009;82 (2):93–105

Bloechl-Daum B Deuson RR Mavros P Hansen M Herrstedt J Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24 (27): 4472–4478

Grunberg SM Deuson RR Mavros P Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100 (10):2261–2268

Fujii H Iihara H Ishihara M Takahashi T Yoshida K Itoh Y Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk. Anticancer Res 2013;33 (12):5549–5556

Blijlevens NM Cytotoxic treatment-induced gastrointestinal symptoms. Curr Opin Support Palliat Care 2007;1 (1):16–22